Indivior Pharmaceuticals Inc
NASDAQ:INDVDrug Manufacturers - Specialty & Generic
+$0.26 today
- Market cap
- $4.53B
- Beta
- 1.17
- P/E (TTM)
- 19.1
- EPS (TTM)
- $2.00
Volume 3.65M
Average 2.08M
INDV Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Indivior Pharmaceuticals IncNASDAQ: INDV
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow growth accelerates
Q2 FY2026 financing cash flow of $173M (cash outflow) rose 3360.0% year over year, ahead of the +278.3% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at -33.3% a year.
Context
- Financing cash flow amounted to 2.4% of revenue in FY2025, down 6.2 pp from a year earlier.
- Financing cash flow grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +3360.0% holds above the trailing-twelve-month pace of +278.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (30M) USD
- Year-over-year change
- +70.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (30M) | +70.6% |
| FY2024 | 2024-12-31 | (102M) | -59.4% |
| FY2023 | 2023-12-31 | (64M) | +36.6% |
| FY2022 | 2022-12-31 | (101M) | -7.4% |
| FY2021 | 2021-12-31 | (94M) | — |
Financing Cash Flow vs competitors
How INDV compares with its peers on the latest reported figures
- INDV's LTM Jun 2026 financing cash flow of $174M is the 2nd largest of the 4 companies compared; the peer median is $31.51M.
- Its year-over-year change of +278.3% is the 3rd highest of 4, against a peer median of +374.0%.
- Financing cash flow amounts to 13.1% of revenue for INDV, versus a peer median of 13.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.51B | +638.5% | — | 86.0% | |
INDVIndivior Pharmaceuticals Inc | LTM Jun 2026 | $174M | +278.3% | -33.3% | 13.1% |
| LTM Mar 2026 | $106.35M | +235.6% | — | 13.4% | |
| LTM Jun 2026 | $31.51M | +374.0% | — | 3.8% | |
| Peer median (excluding INDV) | $31.51M | +374.0% | — | 13.4% | |
Competitors are the stored peer set for INDV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 213M | (44M) | (126M) | 7M | 210M |
| Depreciation & Amortization | 22M | 16M | 15M | 28M | 20M |
| Deferred Income Tax | 0 | 0 | (64M) | 7M | (46M) |
| Stock-Based Compensation | 11M | 16M | 21M | 24M | 26M |
| Change in Working Capital | 173M | 118M | (297M) | (46M) | (257M) |
| Accounts Receivables | (25M) | (21M) | (33M) | (1M) | 3M |
| Inventory | (3M) | (30M) | (6M) | (43M) | 18M |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 201M | 169M | (258M) | (2M) | (278M) |
| Other Non-Cash Items | (66M) | (110M) | 151M | 16M | 20M |
| Operating Cash Flow | 353M | (4M) | (300M) | 36M | (27M) |
| Capital Expenditures | (34M) | (5M) | (53M) | (31M) | (67M) |
| Acquisitions (Net) | 0 | 0 | (129M) | 0 | 0 |
| Purchases of Investments | 0 | (245M) | (45M) | (17M) | (20M) |
| Sales of Investments | 0 | 27M | 129M | 117M | 20M |
| Other Investing Activities | (10M) | 1M | (42M) | (2M) | 0 |
| Investing Cash Flow | (14M) | (222M) | (95M) | 69M | (66M) |
| Debt Repayment | 14M | (3M) | (12M) | 92M | (17M) |
| Common Stock Issued | 1M | (8M) | (19M) | (19M) | (3M) |
| Common Stock Repurchased | (101M) | (90M) | (33M) | (173M) | (11M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (8M) | 0 | 0 | (2M) | 1M |
| Financing Cash Flow | (94M) | (101M) | (64M) | (102M) | (30M) |
| Effect of Forex Changes | (1M) | (1M) | 1M | 0 | (1M) |
| Net Change in Cash | 244M | (328M) | (458M) | 3M | (124M) |
| Free Cash Flow | 319M | (9M) | (353M) | 5M | (94M) |
Indivior Pharmaceuticals Inc
NASDAQ:INDV
Intrinsic Alpha fair value
Locked
Current Price
$36.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.